Kidney Cancer

Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC

Publish Date September 23, 2022

Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse.

COSMIC-313: Triplet Prolongs PFS vs Doublet in Renal Cell Carcinoma

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date September 20, 2022

The PFS benefit was driven primarily by patients with intermediate-risk disease.

Immune Checkpoint Inhibitor Therapy Linked With Improved Quality of Life

By

Natasha Persaud

Publish Date September 1, 2022

Among patients with a variety of solid tumors, investigators found favorable associations of immune checkpoint inhibitor therapy with quality of life compared with no immunotherapy use.

Normonatremia Tied to Outcomes in Metastatic Renal Cell Carcinoma

By

Jonathan Goodman, MPhil

Publish Date August 30, 2022

Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.

Estimating Post-Nephrectomy GFR May Guide Treatment Decisions

By

Natasha Persaud

Publish Date August 26, 2022

An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.